Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01571388 · ClinicalTrials.gov registry record · Phase 1
A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01571388 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 25 participants.
The verdict
NCT01571388, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The study will determine if there are differences in how dacomitinib is absorbed and eliminated between healthy subjects and subjects with mild and moderately impaired hepatic function.
Interventions
- DRUG dacomitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01571388
The ClinicalTrials.gov registry entry for NCT01571388 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dacomitinib is the first listed.
NCT01571388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01571388 about?
NCT01571388 is a clinical study titled "A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment". The study will determine if there are differences in how dacomitinib is absorbed and eliminated between healthy subjects and subjects with mild and moderately impaired hepatic function.
What is the current status of trial NCT01571388?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-04. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01571388?
The interventions under investigation include: dacomitinib (DRUG).
Who is sponsoring clinical trial NCT01571388?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.